Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 06 May 2013 | By Louise Zornoza,
Australia's Therapeutic Goods Administration (TGA) has opened a consultation on proposed amendments to the new regulatory framework for in vitro diagnostic devices (IVDs) that covers both commercially manufactured IVDs and in-house IVDs (those IVDs developed or modified by providers for use in their own laboratories).
Under the new regulatory framework, IVDs are deemed to be medical devices and, unless exempt, must fully comply with the new regulatory requirements as of 1 July 2014. The consultation focuses on four key issues that were identified during the first two years of the transition period (July 2010 to July 2012) leading up to the implementation of the new IVD regulatory framework.
These issues are the:
The deadline for comments is 31 May 2013.
TGA Amendments to IVD Framework
Read all Breaking News from RegLink
Tags: LDTs, Latest News, IVD, australia, medical device